AZURE HEALTH TECHNOLOGY LIMITED(AZT)

The company notifies ASIC of the appointment or cessation of a director or company secretary.

Shareholders in this company should consider crystallising a capital loss in 2024/25 by selling their shares. This process is now much easier and quicker. It can be achieved online by entering transaction details here. While, this usually makes good economic sense we recommend you seek professional advice before buying or selling securities, your accountant is probably the best person.

The company notifies ASIC of the appointment or cessation of a director or company secretary.

company is now called VGI HEALTH TECHNOLOGY LIMITED

delisted from the commencement of trading on 1 May 2020, pursuant to Listing rule 17.12.

we understand this company failed and ASX removed the company from listing because its securities have been suspended from trading for an unacceptably long period

The Directors have resolved to withdraw AZT's application for reinstatement to the official list of ASX. The Company was unable to satisfy the spread condition in ASX Listing Rule 1.1 Condition 8. The offer made under the Replacement Prospectus closed on Friday 17 April 2020. In view of the Directors resolving to withdraw AZT's application for reinstatement to the official list of ASX the listing condition contained in the Prospectus will not be satisfied and the Company is required to comply with section 724 of the Corporations Act 2001. The Company has lodged a Second Supplementary Prospectus with ASIC today 27 April 2020.

The company lodges a Supplementary Prospectus with ASIC to inform shareholders of the correction of drafting errors in the Replacement Prospectus lodged on 12 February 2020. Specifically, this Supplementary Prospectus has been prepared to correct certain drafting errors in the Prospectus which unintentionally restricted the Offer to Applicants resident in Australia. It is intended that the Offer be available in jurisdictions in which it would not be unlawful to make the Offer, as stated in section 6.18 of the Replacement Prospectus.

The Board has resolved to extend the closing date of the offer by 15 business days. ASX has granted an extension to the delisting deadline of 9 April 2020 to 24 April 2020, subject to the following conditions: close of the public offer being conducted pursuant to the company's prospectus; satisfaction of ASX's conditions to reinstatement, namely compliance with Chapters 1 and 2 of ASX Listing Rules; and the company's securities must be reinstated by 24 April 2020. This is the final extension to the the delisting deadline that ASX will grant. Failure by the company to satisfy the requirements will result in the company being removed from the ASX official list. The offer will now close on 15 April 2020 at 5 pm, subject to the right of the company to close the offer early.

we understand that on or about this date the company consolidated its shares 100 for 257

ASX has granted an extension for removal from the official list to 9 April 2020. ASX further advises that if the re-compliance transaction is not completed and the company's securities are not reinstated to trading by 9 April 2020, it will be removed.

The company releases the Results of Meeting.

The company lodges its Half Yearly Report and Accounts.

ASIC has approved the company's replacement prospectus and that the company will proceed with a capital raising via public offer of up to 50 million shares at a price of $0.20 per share to raise up to $10 million. The replacement prospectus is issued fr the purposes of re-complying with the admission requirements under chapters 1 and 2 of the Listing Rules following a change in the nature and scale of the company's activities.

The company releases a notification of consolidation of its securities. Shareholders get 100 shares for every 257 presently owned.

A meeting of shareholders will be held at Suite 3, Level 45, 19-29 Martin Place Sydney NSW 2000 at 10:00am (Sydney time) on 6 March 2020.

The company lodges its Appendix 4C - quarterly.

ASX has granted the company a further extension to the deadline for automatic removal from the ASX official list to allow it additional time to satisfy the requirements for a short extension of the 2 year deadline for automatic removal where an entity is in the final stages of implementing a transaction that will lead to the resumption of trading in its securities as detailed in section 3.4 of ASX Guidance Note 33. The new deadline for satisfying these requirements is 17 March 2020. The company proposes to despatch a notice of meeting on 4 February 2020 for a meeting to be held on 6 March 2020 seeking shareholder approval for the transactions. The company lodged its prospectus with ASIC on 30 January 2020. ASX noted that failure by the company to satisfy the requirements by 17 March 2020 will result in the company being removed from ASX official list.

32,722 unlisted options exercisable at $3.82 per option and 32,722 unlisted options exercisable at $7.64 expired on 31 December 2019.

ASX has granted the Company an extension to the deadline for automatic removal from the ASX official list to allow it additional time to satisfy the requirements for a short extension of the 2 year deadline for automatic removal where an entity is in the final stages of implementing a transaction that will lead to the resumption of trading in its securities. The new deadline for satisfying these requirements is 10 February 2020. The company proposes to despatch a Notice of Meeting to shareholders on 3 January 2020 for a meeting to be held on 3 February 2020 seeking shareholder approval for the transactions. The company proposes to lodge its prospectus with ASIC on 6 January 2020.

The company releases the results of its meeting.

The company has signed a binding, conditional memorandum of understanding with Invictus Biopharma to acquire 100% of the issued capital of Invictus in return for equity in AZT and the assumption of up to $1.2 million of Invictus' net liability to creditors and lenders. The acquisition is in connection with a proposed relisting and capital raising of AZT.

The company lodges its Appendix 4C - quarterly.

The company's AGM will be held at Suite 3, Level 45, 19-29 Martin Place Sydney NSW 2000 at 1:00 pm (Sydney time) on Friday 29 November 2019.

The company lodges an Appendix 4C - quarterly.

The company releases an Appendix 4G.

The company lodges an Appendix 4E.

The company lodges its Annual Report to shareholders.

The company lodges the following reports: Half Yearly Report and Accounts 31/12/16, Annual Report to Shareholders FY 2017, Half Yearly Report and Accounts 31/12/17, Annual Report to Shareholders FY2018 and Half Yearly Report and Accounts 31/12/18.

The company has received approval from ASIC to change its auditors. The company has accepted the resignation of RSM Australia Partners and the consent of Hall Chadwick NSW to its appointment as AZT's auditor.

294,501 unlisted options exercisable at $4.775 per option expired on 30 June 2019.

1,127,882 unlisted options exercisable at $15.28 per option expired on 12 April 2019.

261 unlisted options exercisable at USD435.48 per option expired on 31 December 2018.

The company issues a response to ASX Appendix 3Z Query.

The company lodges its Appendix 4C - quarterly.

Name changed from Moko Social Media Limited